The opioid epidemic continues to affect hundreds of thousands of people, but there may be hope for the future with a new, non ...

The new FDA-approved pain drug is suzetrigine, with the brand name Journavx. Suzetrigine is designed to alleviate moderate to ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating on January 31.Maximize Your ...

The U.S. Food and Drug Administration has approved a novel prescription pain medication that targets sodium channels involved ...

The US Food and Drug Administration has approved suzetrigine (Journavx) 50 mg oral tablets, a first-in-class non-opioid ...

Vertex (VRTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

The FDA has approved a new non-opioid prescription medication, Journavx for adults with moderate to severe acute pain.

Some you might hold only temporarily, while others you own for decades. David Jagielski (Eli Lilly): A forever stock you can ...

President Donald Trump on Saturday finalized tariffs, set to go into effect on Tuesday, at 10 percent on all Chinese goods, ...

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...

Wall Street analysts expect that Journavx, whose active ingredient is suzetrigine, could bring in about $100 million in sales this year. “We believe the opioid epidemic could be a priority for ...

Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming ...